quinolinic acid has been researched along with Amyotrophic Lateral Sclerosis in 8 studies
Quinolinic Acid: A metabolite of tryptophan with a possible role in neurodegenerative disorders. Elevated CSF levels of quinolinic acid are correlated with the severity of neuropsychological deficits in patients who have AIDS.
pyridinedicarboxylic acid : Any member of the class of pyridines carrying two carboxy groups.
quinolinic acid : A pyridinedicarboxylic acid that is pyridine substituted by carboxy groups at positions 2 and 3. It is a metabolite of tryptophan.
Amyotrophic Lateral Sclerosis: A degenerative disorder affecting upper MOTOR NEURONS in the brain and lower motor neurons in the brain stem and SPINAL CORD. Disease onset is usually after the age of 50 and the process is usually fatal within 3 to 6 years. Clinical manifestations include progressive weakness, atrophy, FASCICULATION, hyperreflexia, DYSARTHRIA, dysphagia, and eventual paralysis of respiratory function. Pathologic features include the replacement of motor neurons with fibrous ASTROCYTES and atrophy of anterior SPINAL NERVE ROOTS and corticospinal tracts. (From Adams et al., Principles of Neurology, 6th ed, pp1089-94)
| Excerpt | Relevance | Reference |
|---|---|---|
| " The kynurenine pathway (KP), activated during neuroinflammation, is emerging as a possible contributory factor in ALS." | 7.76 | The kynurenine pathway and inflammation in amyotrophic lateral sclerosis. ( Brew, BJ; Chen, Y; Coggan, S; Cullen, KM; Garner, B; Grant, R; Guillemin, GJ; Meininger, V; Stankovic, R, 2010) |
| "The kynurenine pathway (KP) is a major route of L-tryptophan catabolism leading to production of several neurobiologically active molecules." | 6.43 | Implications for the kynurenine pathway and quinolinic acid in amyotrophic lateral sclerosis. ( Brew, BJ; Guillemin, GJ; Meininger, V, 2005) |
| "Quinolinic acid (QUIN) is a well-known neuroactive metabolite of tryptophan degradation pathway or kynurenine pathway." | 5.48 | Effect of wedelolactone and gallic acid on quinolinic acid-induced neurotoxicity and impaired motor function: significance to sporadic amyotrophic lateral sclerosis. ( Goli, D; S, M; T, P, 2018) |
| " The kynurenine pathway (KP), activated during neuroinflammation, is emerging as a possible contributory factor in ALS." | 3.76 | The kynurenine pathway and inflammation in amyotrophic lateral sclerosis. ( Brew, BJ; Chen, Y; Coggan, S; Cullen, KM; Garner, B; Grant, R; Guillemin, GJ; Meininger, V; Stankovic, R, 2010) |
| "The kynurenine pathway (KP) is a major route of L-tryptophan catabolism leading to production of several neurobiologically active molecules." | 2.43 | Implications for the kynurenine pathway and quinolinic acid in amyotrophic lateral sclerosis. ( Brew, BJ; Guillemin, GJ; Meininger, V, 2005) |
| "EDA is a molecule approved for the treatment of amyotrophic lateral sclerosis (ALS), a neurodegenerative disease associated with an increase of QUIN concentrations in both serum and cerebrospinal fluid." | 1.72 | Chromatographic measurement of 3-hydroxyanthranilate 3,4-dioxygenase activity reveals that edaravone can mitigate the formation of quinolinic acid through a direct enzyme inhibition. ( Altomare, A; Mercolini, L; Mondanelli, G; Protti, M; Regazzoni, L; Sanz, I; Valsecchi, V; Volpi, C, 2022) |
| "Quinolinic acid (QUIN) is a well-known neuroactive metabolite of tryptophan degradation pathway or kynurenine pathway." | 1.48 | Effect of wedelolactone and gallic acid on quinolinic acid-induced neurotoxicity and impaired motor function: significance to sporadic amyotrophic lateral sclerosis. ( Goli, D; S, M; T, P, 2018) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (12.50) | 18.2507 |
| 2000's | 2 (25.00) | 29.6817 |
| 2010's | 4 (50.00) | 24.3611 |
| 2020's | 1 (12.50) | 2.80 |
| Authors | Studies |
|---|---|
| Sanz, I | 1 |
| Altomare, A | 1 |
| Mondanelli, G | 1 |
| Protti, M | 1 |
| Valsecchi, V | 1 |
| Mercolini, L | 1 |
| Volpi, C | 1 |
| Regazzoni, L | 1 |
| S, M | 1 |
| T, P | 1 |
| Goli, D | 1 |
| Lee, JM | 1 |
| Tan, V | 1 |
| Lovejoy, D | 1 |
| Braidy, N | 1 |
| Rowe, DB | 1 |
| Brew, BJ | 4 |
| Guillemin, GJ | 4 |
| Chen, Y | 2 |
| Stankovic, R | 1 |
| Cullen, KM | 1 |
| Meininger, V | 3 |
| Garner, B | 1 |
| Coggan, S | 1 |
| Grant, R | 1 |
| Tan, L | 2 |
| Yu, JT | 1 |
| Milstien, S | 1 |
| Sakai, N | 1 |
| Krieger, C | 1 |
| Vickers, JH | 1 |
| Saito, K | 1 |
| Heyes, MP | 1 |
3 reviews available for quinolinic acid and Amyotrophic Lateral Sclerosis
| Article | Year |
|---|---|
Involvement of quinolinic acid in the neuropathogenesis of amyotrophic lateral sclerosis.
Topics: Amyotrophic Lateral Sclerosis; Animals; Humans; Kynurenine; Metabolic Networks and Pathways; Quinoli | 2017 |
The kynurenine pathway in neurodegenerative diseases: mechanistic and therapeutic considerations.
Topics: Aging; Alzheimer Disease; Amyotrophic Lateral Sclerosis; Animals; Enzyme Inhibitors; Humans; Hunting | 2012 |
Implications for the kynurenine pathway and quinolinic acid in amyotrophic lateral sclerosis.
Topics: Amyotrophic Lateral Sclerosis; Animals; Humans; Inflammation; Kynurenine; Models, Neurological; Moto | 2005 |
5 other studies available for quinolinic acid and Amyotrophic Lateral Sclerosis
| Article | Year |
|---|---|
Chromatographic measurement of 3-hydroxyanthranilate 3,4-dioxygenase activity reveals that edaravone can mitigate the formation of quinolinic acid through a direct enzyme inhibition.
Topics: 3-Hydroxyanthranilate 3,4-Dioxygenase; 3-Hydroxyanthranilic Acid; Amyotrophic Lateral Sclerosis; Eda | 2022 |
Effect of wedelolactone and gallic acid on quinolinic acid-induced neurotoxicity and impaired motor function: significance to sporadic amyotrophic lateral sclerosis.
Topics: Amyotrophic Lateral Sclerosis; Animals; Antioxidants; Apoptosis; Brain; Coumarins; Disease Models, A | 2018 |
The kynurenine pathway and inflammation in amyotrophic lateral sclerosis.
Topics: Adult; Amyotrophic Lateral Sclerosis; Brain; Female; HLA-DR Antigens; Humans; Indoleamine-Pyrrole 2, | 2010 |
Recent advances in the treatment of amyotrophic lateral sclerosis. Emphasis on kynurenine pathway inhibitors.
Topics: Adult; Amyotrophic Lateral Sclerosis; Animals; Brain; D-Aspartic Acid; Functional Laterality; Humans | 2009 |
Cerebrospinal fluid nitrite/nitrate levels in neurologic diseases.
Topics: Alzheimer Disease; Amyotrophic Lateral Sclerosis; Animals; Biopterins; HIV Infections; Humans; Hunti | 1994 |